Business
Zomedica Enters Contract Manufacturing and Services Agreement with Rahm Sensor Development to Expand Revenue Streams Beyond Animal Health
Zomedica Enters Contract Manufacturing and Services Agreement with Rahm Sensor Development to Expand Revenue Streams Beyond Animal Health.
About this update from Zomedica Corp.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Zomedica Enters Contract Manufacturing and Services Agreement with Rahm Sensor Development to Expand Revenue Streams Beyond Animal Health\r\n \r\n \r\n\r\n\r\nZomedica Enters Contract Manufacturing and Services Agreement with Rahm Sensor Development to Expand Revenue Streams Beyond Animal Health\r\n\r\n\r\n\r\n\r\n\r\nAgreement leverages existing infrastructure to add contract-based revenue, improve asset utilization, support long-term cash flow and create shareholder value through diversified markets ANN ARBOR, MI / ACCESS Newswire / January 22, 2026 / Zomedica Corp. (OTCQB:ZOMDF) (\"Zomedica\" or the \"Company\"), an animal health company offering innovative diagnostic and therapeutic devices for equine and companion animals, today announced that it has entered into a contract manufacturing and service agreement with Rahm Sensor Development, a technology company advancing contact-free, multi-sensor monitoring solutions for high-risk environments.\r\n Under the agreement, Zomedica will manufacture Rahm's first commercial product, the Cell-Guardian™, an advanced personnel monitoring device designed to improve safety and situational awareness in high-risk environments. Cell-Guardian™ is currently being deployed in correctional and institutional settings to enhance safety and situational awareness. Zomedica will also provide engineering services on an as-needed basis and Level One customer service, enabling Rahm to accelerate commercialization while leveraging Zomedica's established operational platform.\r\n The agreement expands Zomedica's revenue model beyond the animal health channel by monetizing existing manufacturing and engineering capabilities. Management expects the partnership to generate incremental, contract-based revenue while improving utilization of existing assets and limiting incremental fixed costs.\r\n \"This agreement allows us to generate new revenue by leveraging assets we already own,\" said Larry Heaton, Chief Executive Officer of Zomedica. \"It improves operating leverage, supports cash flow, and aligns with our disciplined approach to diversification without increasing fixed costs. We view this as a practical way to create shareholder value while maintaining focus on our core animal health business.\"\r\n From an investor perspective, the opportunity is supported by the si...